138 related articles for article (PubMed ID: 30999245)
1. Potent and selective EGFR inhibitors based on 5-aryl-7H-pyrrolopyrimidin-4-amines.
Reiersølmoen AC; Aarhus TI; Eckelt S; Nørsett KG; Sundby E; Hoff BH
Bioorg Chem; 2019 Jul; 88():102918. PubMed ID: 30999245
[TBL] [Abstract][Full Text] [Related]
2. Chiral 6-aryl-furo[2,3-d]pyrimidin-4-amines as EGFR inhibitors.
Han J; Kaspersen SJ; Nervik S; Nørsett KG; Sundby E; Hoff BH
Eur J Med Chem; 2016 Aug; 119():278-99. PubMed ID: 27235841
[TBL] [Abstract][Full Text] [Related]
3. Identification of new 4-N-substituted 6-aryl-7H-pyrrolo[2,3-d]pyrimidine-4-amines as highly potent EGFR-TK inhibitors with Src-family activity.
Kaspersen SJ; Han J; Nørsett KG; Rydså L; Kjøbli E; Bugge S; Bjørkøy G; Sundby E; Hoff BH
Eur J Pharm Sci; 2014 Aug; 59():69-82. PubMed ID: 24769040
[TBL] [Abstract][Full Text] [Related]
4. Balancing potency, metabolic stability and permeability in pyrrolopyrimidine-based EGFR inhibitors.
Han J; Henriksen S; Nørsett KG; Sundby E; Hoff BH
Eur J Med Chem; 2016 Nov; 124():583-607. PubMed ID: 27614407
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological activity of N
Kurup S; McAllister B; Liskova P; Mistry T; Fanizza A; Stanford D; Slawska J; Keller U; Hoellein A
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):74-84. PubMed ID: 29115879
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of FAK inhibitors with a 5-fluoro-7H-pyrrolo[2,3-d]pyrimidine scaffold as anti-hepatocellular carcinoma agents.
Tan H; Liu Y; Gong C; Zhang J; Huang J; Zhang Q
Eur J Med Chem; 2021 Nov; 223():113670. PubMed ID: 34214842
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and optimization of substituted furo[2,3-d]-pyrimidin-4-amines and 7H-pyrrolo[2,3-d]pyrimidin-4-amines as ACK1 inhibitors.
Jiao X; Kopecky DJ; Liu J; Liu J; Jaen JC; Cardozo MG; Sharma R; Walker N; Wesche H; Li S; Farrelly E; Xiao SH; Wang Z; Kayser F
Bioorg Med Chem Lett; 2012 Oct; 22(19):6212-7. PubMed ID: 22929232
[TBL] [Abstract][Full Text] [Related]
8. In vitro baselining of new pyrrolopyrimidine EGFR-TK inhibitors with Erlotinib.
Sundby E; Han J; Kaspersen SJ; Hoff BH
Eur J Pharm Sci; 2015 Dec; 80():56-65. PubMed ID: 26296860
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of substituted pyrrolo[2,3-d]pyrimidines as multiple receptor tyrosine kinase inhibitors and antiangiogenic agents.
Gangjee A; Namjoshi OA; Yu J; Ihnat MA; Thorpe JE; Warnke LA
Bioorg Med Chem; 2008 May; 16(10):5514-28. PubMed ID: 18467105
[TBL] [Abstract][Full Text] [Related]
10. Design, Synthesis, and Biological Evaluation of Pyrimido[4,5- d]pyrimidine-2,4(1 H,3 H)-diones as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation.
Hao Y; Lyu J; Qu R; Tong Y; Sun D; Feng F; Tong L; Yang T; Zhao Z; Zhu L; Ding J; Xu Y; Xie H; Li H
J Med Chem; 2018 Jul; 61(13):5609-5622. PubMed ID: 29906114
[TBL] [Abstract][Full Text] [Related]
11. Kinetic and thermodynamic insights into interaction of erlotinib with epidermal growth factor receptor: Surface plasmon resonance and molecular docking approaches.
Mohammadzadeh-Asl S; Aghanejad A; Yekta R; de la Guardia M; Ezzati Nazhad Dolatabadi J; Keshtkar A
Int J Biol Macromol; 2020 Nov; 163():954-958. PubMed ID: 32653374
[TBL] [Abstract][Full Text] [Related]
12. Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain.
Park JH; Liu Y; Lemmon MA; Radhakrishnan R
Biochem J; 2012 Dec; 448(3):417-23. PubMed ID: 23101586
[TBL] [Abstract][Full Text] [Related]
13. Discovery of 4-(Piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine Derivatives as Akt Inhibitors.
Liu Y; Yin Y; Zhang J; Nomie K; Zhang L; Yang D; Wang ML; Zhao G
Arch Pharm (Weinheim); 2016 May; 349(5):356-62. PubMed ID: 26991997
[TBL] [Abstract][Full Text] [Related]
14. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and in vitro anticancer evaluation of some fused indazoles, quinazolines and quinolines as potential EGFR inhibitors.
Abdelsalam EA; Zaghary WA; Amin KM; Abou Taleb NA; Mekawey AAI; Eldehna WM; Abdel-Aziz HA; Hammad SF
Bioorg Chem; 2019 Aug; 89():102985. PubMed ID: 31121559
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as selective Btk inhibitors with improved pharmacokinetic properties for the treatment of rheumatoid arthritis.
He L; Pei H; Zhang C; Shao M; Li D; Tang M; Wang T; Chen X; Xiang M; Chen L
Eur J Med Chem; 2018 Feb; 145():96-112. PubMed ID: 29324347
[TBL] [Abstract][Full Text] [Related]
17. Structural optimization of diphenylpyrimidine scaffold as potent and selective epidermal growth factor receptor inhibitors against L858R/T790M resistance mutation in nonsmall cell lung cancer.
Yi Y; Wang L; Zhao D; Huang S; Wang C; Liu Z; Sun H; Liu K; Ma X; Li Y
Chem Biol Drug Des; 2018 Dec; 92(6):1988-1997. PubMed ID: 30030903
[TBL] [Abstract][Full Text] [Related]
18. 4-Aminoindazolyl-dihydrofuro[3,4-d]pyrimidines as non-covalent inhibitors of mutant epidermal growth factor receptor tyrosine kinase.
Hanan EJ; Baumgardner M; Bryan MC; Chen Y; Eigenbrot C; Fan P; Gu XH; La H; Malek S; Purkey HE; Schaefer G; Schmidt S; Sideris S; Yen I; Yu C; Heffron TP
Bioorg Med Chem Lett; 2016 Jan; 26(2):534-539. PubMed ID: 26639762
[TBL] [Abstract][Full Text] [Related]
19. Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants.
Cheng H; Nair SK; Murray BW; Almaden C; Bailey S; Baxi S; Behenna D; Cho-Schultz S; Dalvie D; Dinh DM; Edwards MP; Feng JL; Ferre RA; Gajiwala KS; Hemkens MD; Jackson-Fisher A; Jalaie M; Johnson TO; Kania RS; Kephart S; Lafontaine J; Lunney B; Liu KK; Liu Z; Matthews J; Nagata A; Niessen S; Ornelas MA; Orr ST; Pairish M; Planken S; Ren S; Richter D; Ryan K; Sach N; Shen H; Smeal T; Solowiej J; Sutton S; Tran K; Tseng E; Vernier W; Walls M; Wang S; Weinrich SL; Xin S; Xu H; Yin MJ; Zientek M; Zhou R; Kath JC
J Med Chem; 2016 Mar; 59(5):2005-24. PubMed ID: 26756222
[TBL] [Abstract][Full Text] [Related]
20. Structure-based design of 2,6,7-trisubstituted-7H-pyrrolo[2,3-d]pyrimidines as Aurora kinases inhibitors.
Le Brazidec JY; Pasis A; Tam B; Boykin C; Wang D; Marcotte DJ; Claassen G; Chong JH; Chao J; Fan J; Nguyen K; Silvian L; Ling L; Zhang L; Choi M; Teng M; Pathan N; Zhao S; Li T; Taveras A
Bioorg Med Chem Lett; 2012 Jun; 22(12):4033-7. PubMed ID: 22607669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]